The Role of EPID in Vivo Dosimetry in the Risk Management of Stereotactic Lung Treatments

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2023 May 31

PMID 37256302

Authors

Marco Esposito

Pietro Mancosu

Andrea Bruschi

Alessandro Ghirelli

Silvia Pini

Paolo Alpi

Raffaella Barca

Camilla Delli Paoli

Fiammetta Meacci

Barbara Grilli Leonulli

Simona Fondelli

Lisa Paoletti

Silvia Scoccianti

Serenella Russo

Affiliations

Soon will be listed here.

Abstract

Background And Objective: In this work we report our experience with the use of in vivo dosimetry (IVD) in the risk management of stereotactic lung treatments.

Methods: A commercial software based on the electronic portal imaging device (EPID) signal was used to reconstruct the actual planning target volume (PTV) dose of stereotactic lung treatments. The study was designed in two phases: i) in the observational phase, the IVD results of 41 consecutive patients were reviewed and out-of-tolerance cases were studied for root cause analysis; ii) in the active phase, the IVD results of 52 patients were analyzed and corrective actions were taken when needed. Moreover, proactive preventions were further introduced to reduce the risk of future failures. The error occurrence rate was analyzed to evaluate the effectiveness of proactive actions.

Results: A total of 330 fractions were analyzed. In the first phase, 13 errors were identified. In the active phase, 12 errors were detected, 5 of which needed corrective actions; in 4 patients the actions taken corrected the error. Several preventions and barriers were introduced to reduce the risk of future failures: the planning checklist was updated, the procedure for vacuum pillows was improved, and use of the respiratory compression belt was optimized. A decrease in the failure rate was observed, showing the effectiveness of procedural adjustment.

Conclusion: The use of IVD allowed the quality of lung stereotactic body radiation therapy (SBRT) treatments to be improved. Patient-specific and procedural corrective actions were successfully taken as part of risk management, leading to an overall improvement in the dosimetric accuracy.

Citing Articles

A commissioning protocol for portal imaging-based radiotherapy in vivo dosimetry systems.

Esposito M, Baldoni R, Bossuyt E, Bresciani S, Clark C, Jones M Phys Imaging Radiat Oncol. 2024; 32:100666.

PMID: 39624392 PMC: 11609462. DOI: 10.1016/j.phro.2024.100666.

References

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J . Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303(11):1070-6. PMC: 2907644. DOI: 10.1001/jama.2010.261. View

Gomez D, Blumenschein Jr G, Lee J, Hernandez M, Ye R, Camidge D . Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016; 17(12):1672-1682. PMC: 5143183. DOI: 10.1016/S1470-2045(16)30532-0. View

Albert J, Das P . Quality indicators in radiation oncology. Int J Radiat Oncol Biol Phys. 2012; 85(4):904-11. DOI: 10.1016/j.ijrobp.2012.08.038. View

Mancosu P, Nicolini G, Goretti G, De Rose F, Franceschini D, Ferrari C . Applying Lean-Six-Sigma Methodology in radiotherapy: Lessons learned by the breast daily repositioning case. Radiother Oncol. 2018; 127(2):326-331. DOI: 10.1016/j.radonc.2018.02.019. View

Esposito M, Villaggi E, Bresciani S, Cilla S, Falco M, Garibaldi C . Estimating dose delivery accuracy in stereotactic body radiation therapy: A review of in-vivo measurement methods. Radiother Oncol. 2020; 149:158-167. DOI: 10.1016/j.radonc.2020.05.014. View

Mijnheer B, Gonzalez P, Olaciregui-Ruiz I, Rozendaal R, Van Herk M, Mans A . Overview of 3-year experience with large-scale electronic portal imaging device-based 3-dimensional transit dosimetry. Pract Radiat Oncol. 2015; 5(6):e679-87. DOI: 10.1016/j.prro.2015.07.001. View

Piermattei A, Greco F, Grusio M, Menna S, Azario L, Stimato G . A validation study of a dedicated software for an automated in vivo dosimetry control in radiotherapy. Med Biol Eng Comput. 2018; 56(10):1939-1947. DOI: 10.1007/s11517-018-1822-3. View

Celi S, Costa E, Wessels C, Mazal A, Fourquet A, Francois P . EPID based in vivo dosimetry system: clinical experience and results. J Appl Clin Med Phys. 2016; 17(3):262-276. PMC: 5690938. DOI: 10.1120/jacmp.v17i3.6070. View

Nailon W, Welsh D, McDonald K, Burns D, Forsyth J, Cooke G . EPID-based in vivo dosimetry using Dosimetry Check™: Overview and clinical experience in a 5-yr study including breast, lung, prostate, and head and neck cancer patients. J Appl Clin Med Phys. 2018; 20(1):6-16. PMC: 6333145. DOI: 10.1002/acm2.12441. View

10.

Bossuyt E, Weytjens R, Nevens D, De Vos S, Verellen D . Evaluation of automated pre-treatment and transit in-vivo dosimetry in radiotherapy using empirically determined parameters. Phys Imaging Radiat Oncol. 2021; 16:113-129. PMC: 7807610. DOI: 10.1016/j.phro.2020.09.011. View

11.

Esposito M, Piermattei A, Bresciani S, Orlandini L, Falco M, Giancaterino S . Improving dose delivery accuracy with EPID in vivo dosimetry: results from a multicenter study. Strahlenther Onkol. 2021; 197(7):633-643. DOI: 10.1007/s00066-021-01749-6. View

12.

MacDougall N, Graveling M, Hansen V, Brownsword K, Morgan A . In vivo dosimetry in UK external beam radiotherapy: current and future usage. Br J Radiol. 2017; 90(1072):20160915. PMC: 5605079. DOI: 10.1259/bjr.20160915. View

13.

Benedict S, Yenice K, Followill D, Galvin J, Hinson W, Kavanagh B . Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010; 37(8):4078-101. DOI: 10.1118/1.3438081. View

14.

Hanna G, Murray L, Patel R, Jain S, Aitken K, Franks K . UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clin Oncol (R Coll Radiol). 2017; 30(1):5-14. DOI: 10.1016/j.clon.2017.09.007. View

15.

Esposito M, Bruschi A, Bastiani P, Ghirelli A, Pini S, Russo S . Characterization of EPID software for VMAT transit dosimetry. Australas Phys Eng Sci Med. 2018; 41(4):1021-1027. DOI: 10.1007/s13246-018-0693-0. View

16.

Esposito M, Ghirelli A, Pini S, Alpi P, Barca R, Fondelli S . Clinical implementation of 3D in vivo dosimetry for abdominal and pelvic stereotactic treatments. Radiother Oncol. 2020; 154:14-20. DOI: 10.1016/j.radonc.2020.09.011. View

17.

Baehr A, Hummel D, Gauer T, Oertel M, Kittel C, Loser A . Risk management patterns in radiation oncology-results of a national survey within the framework of the Patient Safety in German Radiation Oncology (PaSaGeRO) project. Strahlenther Onkol. 2022; 199(4):350-359. PMC: 10033570. DOI: 10.1007/s00066-022-01984-5. View

18.

Huq M, Fraass B, Dunscombe P, Gibbons Jr J, Ibbott G, Mundt A . The report of Task Group 100 of the AAPM: Application of risk analysis methods to radiation therapy quality management. Med Phys. 2016; 43(7):4209. PMC: 4985013. DOI: 10.1118/1.4947547. View

19.

Schmitt D, Blanck O, Gauer T, Fix M, Brunner T, Fleckenstein J . Technological quality requirements for stereotactic radiotherapy : Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy. Strahlenther Onkol. 2020; 196(5):421-443. PMC: 7182540. DOI: 10.1007/s00066-020-01583-2. View

20.

Guckenberger M, Andratschke N, Dieckmann K, Hoogeman M, Hoyer M, Hurkmans C . ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol. 2017; 124(1):11-17. DOI: 10.1016/j.radonc.2017.05.012. View